Humanin: The Mitochondrial-Derived Peptide Redefining Cytoprotection Research

Introduction: A Peptide Encoded by Mitochondrial DNA

Humanin (HN) occupies a unique position in peptide research as the first identified member of a novel class known as mitochondrial-derived peptides (MDPs). Unlike the vast majority of known bioactive peptides, which are encoded by the nuclear genome, humanin is encoded by a short open reading frame (sORF) within the 16S ribosomal RNA region of the mitochondrial genome (Hashimoto et al., 2001).

For dosing, reconstitution, and protocol details, see our Humanin Dosage Protocol Guide: Mitochondrial Cytoprotection Research 2026.

This discovery fundamentally challenged the long-held view that mitochondria function solely as cellular power plants. The identification of humanin suggested that mitochondria actively communicate with the rest of the cell through secreted peptide signals — a concept now referred to as mitochondrial retrograde signaling (Lee et al., 2013).

Humanin is a 24-amino acid peptide with the sequence MAPRGFSCLLLLTSEIDLPVKRRA (in the cytoplasmic/secreted form). It has since been detected in a wide range of tissues in laboratory investigations, and circulating levels have been measured in various biological fluids, establishing it as a secreted retrograde signal factor. Alongside MOTS-c, humanin represents one of the two most extensively characterized mitochondrial-derived peptides in current research.

Discovery and Historical Context

The story of humanin begins in 2001, when Hashimoto and colleagues employed a functional expression screening strategy — a modified "death-trap" assay — to identify factors capable of rescuing neuronal cells from toxicity associated with familial Alzheimer's disease (FAD) gene products. From cDNA libraries derived from the occipital cortex of an unaffected region of an Alzheimer's patient's brain, they isolated a clone encoding a short polypeptide that potently suppressed cell death induced by multiple FAD-related gene variants and amyloid-beta (Aβ) peptides (Hashimoto et al., 2001).

The peptide was named "humanin" by Professor Nishimoto's laboratory to reflect its potential to restore "humanity" to those affected by neurodegeneration — a poetic naming convention unusual in biochemistry.

Shortly after this initial discovery, two independent research groups identified humanin through yeast two-hybrid screening as a binding partner of:

1. IGFBP-3 (Insulin-like Growth Factor Binding Protein 3) — a major IGF-I binding protein with both circulating and intracellular roles

2. Bax — a pro-apoptotic member of the Bcl-2 family critical for mitochondrial-mediated programmed cell death

These parallel discoveries immediately positioned humanin at the intersection of growth factor signaling and apoptosis regulation, two of the most intensely studied areas in cell biology.

Molecular Structure and Key Residues

Humanin is a 24-amino acid peptide with a molecular weight of approximately 2.7 kDa. Structural studies using NMR spectroscopy have revealed that in aqueous solution, humanin adopts a largely disordered conformation, though it can form partial helical structures in membrane-mimetic environments.

Critical Functional Residues

Structure-activity relationship (SAR) studies have identified several residues essential for humanin's biological activities:

• •Cys8: Important for self-dimerization via disulfide bond formation; mutation to proline (C8P) reduces Bax-binding capacity
• •Ser14: A pivotal residue — substitution with glycine (S14G) produces the analog HNG, which exhibits approximately 1,000-fold greater neuroprotective activity than wild-type humanin (Hashimoto et al., 2001)
• •Ser7: Mutation to alanine (S7A) produces a functionally inactive analog, serving as a critical negative control in research
• •Phe6 and Lys21: Essential for IGFBP-3 binding activity (Njomen et al., 2015)
• •Leu9, Leu10, Leu11, Pro19, Val20: Required for proper secretion of the peptide

The correlation between structural stability at physiological temperature (37°C) and biological activity is particularly noteworthy: S14G-HN (most active) is the most structurally stable, wild-type HN is intermediate, and S7A-HN (inactive) is the least stable (Arakawa et al., 2011). This suggests that conformational persistence under physiological conditions is a key determinant of humanin's functional potency.

Mechanisms of Action

Humanin exerts its cytoprotective effects through multiple signaling pathways, acting both intracellularly and extracellularly. This multi-modal mechanism distinguishes it from most single-target peptide ligands.

Extracellular Receptor Signaling: The Trimeric Receptor Complex

Humanin signals through a trimeric receptor complex composed of:

• •CNTFR-α (Ciliary Neurotrophic Factor Receptor alpha)
• •gp130/IL6ST (Interleukin-6 Signal Transducer)
• •WSX-1 (IL-27 receptor alpha chain)

Binding to this receptor complex activates the JAK2/STAT3 signaling cascade, which is central to humanin's cytoprotective effects. Research has demonstrated that humanin acts through the gp130/IL6ST receptor complex to activate three major downstream pathways (Kim et al., 2016):

1. AKT (Protein Kinase B) — pro-survival signaling

2. ERK1/2 (Extracellular Signal-Regulated Kinases) — cell proliferation and differentiation

3. STAT3 (Signal Transducer and Activator of Transcription 3) — transcriptional activation of survival genes

Intracellular Targets

Beyond receptor-mediated signaling, humanin interacts with key intracellular proteins:

• •Bax binding: Humanin directly binds the pro-apoptotic protein Bax, preventing its translocation to the mitochondrial membrane and subsequent cytochrome c release. This represents a direct anti-apoptotic mechanism independent of receptor signaling.
• •IGFBP-3 interaction: By binding IGFBP-3, humanin prevents the nuclear translocation of IGFBP-3 via importin-β, thereby blocking IGFBP-3-induced apoptosis (Njomen et al., 2015).
• •VSTM2L binding: Humanin also interacts with V-set and transmembrane domain containing 2-like protein (VSTM2L), which modulates its cytoprotective activity.

Chaperone-Like Activity

An additional mechanism was identified when researchers found that humanin analogs, including HNG (S14G-Humanin), exhibit chaperone-like activity — the ability to prevent protein misfolding and aggregation ([Minber et al., 2017]()). This property is particularly relevant in the context of protein aggregation-related research, as it suggests humanin may directly interact with misfolded protein species.

Key Analogs and Derivatives

The development of humanin analogs has been critical to advancing research in this field, enabling investigators to dissect individual mechanistic pathways and enhance potency.

HNG ([Gly14]-Humanin / S14G-Humanin)

HNG is the most widely studied humanin analog. The single substitution of serine-14 with glycine produces a peptide with approximately 1,000-fold greater neuroprotective potency and enhanced structural stability compared to wild-type humanin. HNG has been demonstrated to:

• •Reactivate JAK2/STAT3 signaling through the PI3K/AKT pathway in oxygen-glucose deprivation models (Gao et al., 2017)
• •Prevent amyloid-beta-induced memory-related changes in murine models (Kawasumi et al., 2005)
• •Reduce amyloid-beta-induced toxicity and mitochondrial ROS production in neuronal cell lines (Conte et al., 2018)

HN-C8P (Cys8Pro)

This analog lacks the ability to form disulfide-mediated dimers and has reduced Bax-binding capacity. It retains partial protective activity, making it useful for distinguishing Bax-dependent and Bax-independent cytoprotective mechanisms.

HN-S7A (Ser7Ala)

The inactive analog serves as a critical negative control. Loss of activity correlates with reduced structural stability, supporting the relationship between conformational integrity and function.

Colivelin

A hybrid peptide combining a partial ADNF (Activity-Dependent Neurotrophic Factor) sequence with the active core of humanin. Colivelin has shown enhanced neuroprotective properties compared to either component alone in laboratory studies, and represents a rational design approach to improving MDP-based research tools.

Research Applications

Neuroprotection and Neuroscience Research

Humanin's origins as a neuroprotective factor continue to drive a significant body of research. Key areas of investigation include:

• •Amyloid-beta toxicity models: Humanin and HNG have been shown to protect neuronal cell lines against Aβ-induced oxidative stress, mitochondrial dysfunction, and cell death across numerous in vitro studies.
• •Cognitive aging: Research in murine models demonstrated that HNG administration was associated with attenuation of age-related cognitive decline. In parallel observational studies, higher circulating humanin levels correlated with improved cognitive age scores in human cohorts (Conte et al., 2018).
• •Ischemic stress models: HNG has been studied in oxygen-glucose deprivation/reoxygenation (OGD/R) models, where it demonstrated cytoprotective effects through JAK2/STAT3 reactivation (Gao et al., 2017).

Cardiovascular Research

Humanin's cytoprotective properties extend to the cardiovascular system:

• •Endothelial cell protection: Humanin mRNA has been detected in human aortic endothelial cells (HAECs). Pre-incubation with humanin reduced oxidized LDL (Ox-LDL)-induced reactive oxygen species (ROS) formation and apoptosis by approximately 50% in vitro (Bachar et al., 2010).
• •Atherosclerosis models: In ApoE-deficient mice maintained on a high-cholesterol diet, humanin administration was associated with preserved endothelial function and attenuated plaque progression (Oh et al., 2011).
• •Coronary endothelial function: Observational data suggest that circulating humanin levels correlate with preserved coronary endothelial function (Widmer et al., 2013).

Metabolic Research

As a mitochondrial-derived peptide, humanin intersects with key metabolic pathways:

• •Insulin sensitivity: Humanin has been shown to enhance insulin-stimulated glucose uptake in certain cell-based models, with effects mediated partially through IGFBP-3 interaction.
• •Metabolic stress: Humanin's relationship with the GH/IGF-I axis — particularly its modulation of IGFBP-3 bioavailability — places it at a critical node in metabolic regulation research.
• •Autophagy: A recent review has highlighted humanin's potential role in regulating autophagy pathways, with implications for metabolic disorder research (2025 review).

Aging and Longevity Research

Perhaps the most compelling aspect of humanin biology is its relationship with aging:

• •Age-related decline: Across multiple species, circulating humanin levels have been observed to decline with age, paralleling the age-related decline of many other mitochondrial functions.
• •Centenarian offspring studies: In a landmark observational study, children of centenarians — individuals statistically more likely to achieve exceptional longevity themselves — were found to have significantly higher circulating humanin levels compared to age-matched controls (Yen et al., 2020).
• •Naked mole-rat connection: The naked mole-rat (Heterocephalus glaber), a model of negligible senescence with extraordinary longevity for its body size, maintains surprisingly stable humanin levels throughout its lifespan, in contrast to the age-related decline observed in other species (Yen et al., 2020).
• •C. elegans lifespan studies: Overexpression of humanin in C. elegans was sufficient to extend lifespan in a daf-16/FOXO-dependent manner, providing direct experimental evidence for a role in longevity (Yen et al., 2020).
• •APOE4 resilience: A humanin variant (P3S) has been found to be specifically enriched in centenarians carrying the APOE4 allele, suggesting a potential protective interaction in the context of genetic risk factors for neurodegeneration (Yen et al., 2024).

Relationship to Other Mitochondrial-Derived Peptides

Humanin was the founding member of the MDP family, paving the way for the discovery of additional mitochondrial genome-encoded peptides:

MOTS-c

MOTS-c (Mitochondrial Open Reading Frame of the Twelve S rRNA type-c) is encoded by the 12S rRNA region of the mitochondrial genome, distinct from humanin's 16S rRNA origin. While humanin primarily acts through receptor-mediated signaling and direct protein-protein interactions, MOTS-c exerts its effects largely through AMPK activation and nuclear translocation to regulate stress-responsive gene expression. Both peptides decline with age and have been linked to metabolic regulation, but through different mechanistic pathways.

Small Humanin-Like Peptides (SHLPs)

Six additional small humanin-like peptides (SHLP1-6) have been identified from sORFs near the humanin coding region within the 16S rRNA gene. SHLP2, in particular, has demonstrated cytoprotective and metabolic regulatory properties similar to humanin, including chaperone-like activity. The SHLPs represent an expanding family of mitochondrial microproteins with overlapping but distinct biological profiles.

Considerations for Laboratory Research

Handling and Stability

• •Solubility: Humanin and its analogs are generally soluble in aqueous buffers. For stock solutions, reconstitution in sterile water or PBS at neutral pH is typically recommended.
• •Storage: Lyophilized peptide should be stored desiccated at -20°C or below. Reconstituted solutions should be aliquoted to minimize freeze-thaw cycles. Refer to our peptide storage guide for detailed protocols.
• •Structural stability: As noted above, the S14G substitution (HNG) confers significantly greater conformational stability at physiological temperature, which may be advantageous for extended in vitro assays.

Quality Verification

Given the short sequence length (24 amino acids), humanin and its analogs are amenable to standard peptide quality control methods:

• •HPLC purity analysis: Essential for confirming peptide homogeneity. See our HPLC and mass spectrometry guide for methodology details.
• •Mass spectrometry: Molecular weight confirmation via MALDI-TOF or ESI-MS is critical for verifying correct synthesis, particularly for analog variants where single amino acid substitutions define activity.
• •Certificate of Analysis (COA): Always request and review COAs from suppliers. Our COA interpretation guide provides a detailed framework for evaluating peptide quality documentation.

Research Design Considerations

• •Active vs. inactive controls: The availability of well-characterized inactive (S7A-HN) and hyperactive (S14G-HN/HNG) analogs makes humanin an excellent system for controlled mechanistic studies.
• •Pathway dissection: Analogs with selective loss of Bax binding (C8P), IGFBP-3 binding (F6A), or dimerization capacity (S7A) enable precise pathway delineation.
• •Cross-reference with MOTS-c: For studies investigating mitochondrial retrograde signaling broadly, MOTS-c provides a complementary MDP with distinct but overlapping downstream effects.

Current Research Landscape and Future Directions

The humanin field continues to expand, with several active frontiers:

1. Biomarker development: The consistent correlation between circulating humanin levels and age-related outcomes across species makes it a candidate biomarker for biological aging and mitochondrial health.

2. Analog optimization: Rational design of humanin derivatives with improved stability, selectivity, and potency remains an active area of medicinal chemistry research.

3. Mitochondrial genomics: The discovery that the mitochondrial genome encodes bioactive peptides beyond its known protein-coding genes has opened an entirely new field of mitochondrial microproteomics, with humanin as its prototype.

4. Cross-kingdom conservation: Humanin-like sequences have been identified across animal species, suggesting deep evolutionary conservation of mitochondrial peptide signaling — a finding with implications for comparative biology and evolutionary research.

5. Integrative MDP research: Understanding how humanin, MOTS-c, and the SHLPs interact as a coordinated mitochondrial signaling network represents perhaps the most ambitious frontier in this field.

Summary

Humanin stands as a landmark discovery in peptide biology — the first peptide shown to be encoded by the mitochondrial genome and actively secreted as a retrograde signaling factor. Its multi-pathway cytoprotective mechanisms, the availability of well-characterized analogs spanning a 1,000-fold activity range, and its compelling associations with aging and longevity make it one of the most versatile research tools in modern peptide science. For investigators interested in mitochondrial signaling, cytoprotection, or aging biology, humanin and its analogs offer a uniquely tractable system for mechanistic investigation.

---

This article is intended for research and educational purposes only. Humanin and its analogs are research compounds intended for laboratory investigation. All references link to peer-reviewed publications indexed in PubMed or major scientific journals.

Research Tools

Researchers sourcing this peptide for laboratory investigation can use the peptide price comparison tool to identify research-grade material from verified suppliers. For reconstitution planning, the peptide calculator provides molar mass, concentration, and dilution calculations.

Research Context: Humanin in the Peptide Research Landscape

Humanin represents a unique target within the broader peptide research ecosystem. Unlike more commonly studied compounds (GLP-1 agonists, GHRP secretagogues), mitochondrial-derived peptides and metabolic regulatory peptides occupy a less commercialized but potentially high-value research niche.

Comparative research positioning:

• •Published research articles on Humanin mechanisms (PubMed): indexed at both endocrine and cellular biology journals
• •Supplier availability: Limited to 2–4 specialized research vendors (compared to 50+ suppliers for semaglutide)
• •Research protocol adoption: Growing in gerontology and metabolic disease research communities
• •Regulatory pathway: Research-grade compound with no approved pharmaceutical formulation in most markets

Cross-peptide research opportunities:

Humanin frequently appears in research contexts alongside related metabolic regulators:

• •Glucagon — coordinate glucose homeostasis regulation
• •Mitochondrial-targeted compounds — synergistic cytoprotection pathways
• •MOTS-c — sister mitochondrial-derived peptide with distinct organ tropism

This positioning creates research protocol optimization opportunities where Humanin can be paired with complementary compounds for mechanistic synergy studies.

References

1. Hashimoto Y, et al. "A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer's disease genes and Abeta." Proc Natl Acad Sci USA. 2001;98(11):6336-6341. PubMed

2. Lee C, et al. "Humanin: a harbinger of mitochondrial-derived peptides?" Trends Endocrinol Metab. 2013;24(5):222-228. PubMed

3. Yen K, et al. "The mitochondrial derived peptide humanin is a regulator of lifespan and healthspan." Aging (Albany NY). 2020;12(12):11185-11199. PubMed

4. Zuccato CF, et al. "Mitochondrial-derived peptide humanin as therapeutic target in cancer and degenerative diseases." Expert Opin Ther Targets. 2019;23(2):117-126. PubMed

5. Gao GS, et al. "Humanin analogue, S14G-humanin, has neuroprotective effects against OGD/R by reactivating Jak2/Stat3 signaling through the PI3K/AKT pathway." Exp Ther Med. 2017;14(4):3926-3934. PubMed

6. Njomen E, et al. "Humanin Peptide Binds to IGFBP3 and Regulates Its Interaction with Importin-β." Protein Pept Lett. 2015;22(10):869-876. PubMed

7. Arakawa T, et al. "The biological activity of Humanin analogs correlates with structure stabilities in solution." Int J Biol Macromol. 2011;49(1):93-97. PubMed

8. Bachar AR, et al. "Humanin is expressed in human vascular walls and has a cytoprotective effect against oxidized LDL-induced oxidative stress." Cardiovasc Res. 2010;88(2):360-366. PubMed

9. Oh YK, et al. "Humanin preserves endothelial function and prevents atherosclerotic plaque progression in hypercholesterolemic ApoE deficient mice." Atherosclerosis. 2011;219(1):65-73. PubMed

10. Conte M, et al. "Humanin Prevents Age-Related Cognitive Decline in Mice and is Associated with Improved Cognitive Age in Humans." Sci Rep. 2018;8:14212. PubMed

11. Kawasumi M, et al. "A humanin derivative, S14G-HN, prevents amyloid-beta-induced memory impairment in mice." J Neurosci Res. 2005;79(5):714-723. PubMed

---

Further Reading:

• •Mitochondrial-Derived Peptides Compared: Humanin vs MOTS-c vs SS-31 in Aging and Cytoprotection Research
• •Galanin: The Pleiotropic Neuropeptide Bridging Neuroscience, Metabolic, Pain, and Oncology Research
• •SS-31 (Elamipretide): Mitochondria-Targeted Tetrapeptide for Bioenergetic Research
• •MOTS-c: Mitochondrial-Derived Peptide for Metabolic Homeostasis Research
• •Reconstitution Calculator
• •Peptide Stack Builder

Live Research Peptide Pricing Snapshot: Humanin (September 2026)

Pricing below is pulled directly from Peptides.SO's live supplier database. Across 21 active supplier listings, per-mg pricing spans a wide range depending on quantity tier and vendor:

Data sourced from Peptides.SO live listings, September 2026. Prices subject to change. All products Research Use Only (RUO).

The wide spread reflects humanin's status as a lower-volume research compound. Bulk vials (5-10 mg) offer dramatically lower per-mg pricing. See live, continuously updated offers at the Humanin price comparison page.

Frequently Asked Questions

Is humanin FDA-approved for any use?

No. Humanin has no FDA-approved indication. It is sold and studied exclusively as a research use only (RUO) compound; no human therapeutic application is approved in the United States (Muzumdar & Barzilai review, PMID 33130077).

How is humanin different from other mitochondrial-derived peptides like MOTS-c?

Both are encoded within mitochondrial DNA rather than nuclear DNA, but they arise from different reading frames (humanin from the 16S rRNA region, MOTS-c from the 12S rRNA region) and act through distinct receptor systems. See our Humanin vs MOTS-c vs SS-31 comparison for a full mechanistic breakdown.

What research areas is humanin most associated with?

Cytoprotection and apoptosis-resistance research is the largest body of literature (Life Sciences review, PMID 33130077), with substantial secondary interest in cardiovascular research (Archives of Cardiovascular Diseases, PMID 32680738) and oncology/neurodegeneration research (Expert Opinion on Therapeutic Targets, PMID 30582721).

Why does humanin pricing vary so much between suppliers?

Batch size, synthesis route (solid-phase vs. recombinant), and third-party CoA verification all affect cost. Because humanin is a lower-volume research peptide relative to compounds like BPC-adjacent or GLP-1 analogs, per-mg costs are more sensitive to individual supplier overhead than commodity-scale compounds.

Does humanin have known research-grade analogs?

Yes — see the Key Analogs and Derivatives section above for HNG and other engineered variants studied for enhanced receptor affinity in preclinical models.

Where can researchers track current humanin supplier pricing?

The live Humanin listing page aggregates current offers across all tracked suppliers in real time, updated continuously as new listings and price changes are captured.